NCT07174726View on ClinicalTrials.gov

A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa

PHASE2RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 10, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

December 15, 2030

Conditions
X-Linked Retinitis Pigmentosa (XLRP)
Interventions
BIOLOGICAL

Adeno-associated virus vector expressing a human RPGR gene

Male participants 12-50 years of age treated by subretinal injection with the dose of AGTC-501

Trial Locations (6)

27710

NOT_YET_RECRUITING

Duke Eye Center, Durham

32209

NOT_YET_RECRUITING

University of Florida Jacksonville Ophthalmology, Jacksonville

33136

NOT_YET_RECRUITING

Bascom Palmer Eye Institute, Miami

45242

NOT_YET_RECRUITING

Cincinnati Eye Institute, Cincinnati

75231

RECRUITING

Retina Foundation of the Southwest, Dallas

97239

NOT_YET_RECRUITING

OHSU Casey Eye Institute, Portland

Sponsors
All Listed Sponsors
lead

Beacon Therapeutics

INDUSTRY

NCT07174726 - A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa | Biotech Hunter | Biotech Hunter